Great Point Partners LLC
Annual return '25
+18.5%
SPY '25
+17.7%
Alpha
+0.8ptsvs SPY
Invested
$435.1M
Holdings
42
Trades YTD
0
Performance · Fund vs SPY
Cumulative return · quarterly snapshotsCoverage 100%. 4 quarters of 2025 measured against SPY adj-close benchmark.
Top holdings · current snapshot
Source: 13F-HR01
$APGE
APOGEE THERAPEUTICS INC
Q3 2025: New position (304.0k shares)
7.2%
02
$VOR
VOR BIOPHARMA INC
Held since at least Q1 2024
7.2%
03
$ZURA
ZURA BIO LTD
Q3 2025: Increased +20.4% (3.17M → 3.82M shares)
5.8%
04
$AMLX
AMYLYX PHARMACEUTICALS INC
Q3 2025: Sold 15.0% (2.00M → 1.70M shares)
5.6%
05
$IBRX
IMMUNITYBIO INC
Held since at least Q1 2024
5.3%
06
$NKTR
NEKTAR THERAPEUTICS
Q3 2025: New position (300.0k shares)
5.2%
07
$SLGL
SOL-GEL TECHNOLOGIES LTD
Held since at least Q1 2024
5.0%
08
$ALMS
ALUMIS INC
Held since at least Q1 2024
4.3%
09
$DRUG
BRIGHT MINDS BIOSCIENCES INC
Held since at least Q1 2024
3.7%
10
$ANNX
ANNEXON INC
Held since at least Q1 2024
3.2%
Recent trades · Last 90 days
No Form 4 / 13D / 13G trade events on file in the recent window. 13F filers report position snapshots quarterly rather than per-trade events, so this section is most useful for managers who also file Form 4 or 13D/G.
Convergence · Pattern Engine ships in v1.1
30-day windowIn development
Convergence participation lands with the Pattern Engine.
Once the Pattern Engine ships, this section will list every active convergence event this fund is named in — with the other named funds, the Congress members on the same name, and combined position size.
Source data: SEC EDGAR · 13F-HR filings · Performance through 2025-12-31 · Last refreshed 10:37 UTC.